Compare Kraft Heinz Co (KHC) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kraft Heinz Co vs ResMed Inc. — how do they compare? Kraft Heinz Co trades at $22.27 (market cap $26.66B), while ResMed Inc. trades at $230.28 (market cap $31.89B). The key difference: ResMed Inc. is the larger of the two by market cap, and Kraft Heinz Co pays the higher dividend (7.12%). Which is the better fit depends on your goals — on Pluang, investors hold Kraft Heinz Co for 129 Days and ResMed Inc. for 51 Days on average.
| KHC | RMD | |
|---|---|---|
Market Cap | $26.66B | $31.89B |
Volume | 31,300,109 | 618,314 |
Sector | Consumer Staples | Health |
52-Week High | $27.62 | $277.88 |
52-Week Low | $21.21 | $182.82 |
Typical Hold Time | 129 Days | 51 Days |
Enterprise Value | $42.98B | $31.24B |
Dividend Yield | 7.12% | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kraft Heinz (KHC) trades at $22.08, up 0.45% on the day, with a bearish technical outlook despite recent earnings beats. The stock shows mixed signals with a low P/E of 13.04 and P/B of 0.74, but negative profitability metrics including a net income margin of -13.64% and ROE of -8.78% reflect challenges from a recent $5.85B net loss in 2025. The company maintains strong operating cash flow of $4.46B and a dividend yield near 6.5%, supported by ongoing brand reinvestment efforts.
The investment outlook is cautious; valuation discounts may attract value investors, but persistent volume declines and high debt pose significant risks. Analyst consensus is mixed with a $24.50 price target, yet only 11.43% recommend buying. Key catalysts include successful turnaround execution and new product launches, though competitive pressures and margin recovery remain critical hurdles for sustained shareholder value.
ResMed (RMD) trades at $230.91, up 2.18% today, with a bullish technical signal and strong fundamentals. The company reported consistent earnings beats in recent quarters, with Q3 2026 EPS expected at $2.68. Revenue grew to $5.15B in 2025, with a net income margin of 26.94%. Analyst consensus is a buy, with a $242.70 price target. Recent news highlights EPS growth targets of 12%-14% and participation in investor conferences.
Outlook is positive due to robust earnings growth and market share gains, but risks include competitive pressures and regulatory investigations. The stock offers upside to the consensus target, supported by institutional buying and solid cash flow generation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kraft Heinz Co
In July 2015, Kraft merged with Heinz to create the third-largest food and beverage manufacturer in North America behind PepsiCo and Nestle and the fifth-largest player in the world. Beyond its namesake brands, the combined firm's portfolio includes Oscar Mayer, Velveeta, and Philadelphia. Outside North America, the firm's global reach includes a distribution network in Europe and emerging markets that drive around one fifth of its consolidated sales base, as its products are sold in more than 190 countries and territories.
Read more on KHC →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
